AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 3 analysts
Fundamentals
Fundamentals institutional score is 66 using growth durability 66.4.
Valuation
Valuation institutional score is 0 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 59 using mean target upside -3.8%; dispersion penalty 12.1; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 0 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 2 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. fundamentals provide support, while valuation and technical structure remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 136.8% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +3.82). Confidence: 65%.
Live forward EPS implies next-12-month EPS of ₹19.98. Applying the stock's normalized valuation corridor produces a fair range of ₹350.85 to ₹553.65, with base value near ₹448.15 (-44.3% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹19.98
Forward P/E
40.3x
Base Fair Value
₹448.15
Fair Range
₹350.85 - ₹553.65
Upside To Base
-44.3%
Estimate Source
Live forward EPS
Growth Estimate
+115.4%
5Y Average
19.17
Current
53.11
Overvalued
27.71
Undervalued
17.56
5Y Average
12.42
Current
34.40
Overvalued
15.38
Undervalued
7.89
5Y Average
3.38
Current
9.36
Overvalued
4.18
Undervalued
2.14
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 39.4x Fair | +8% vs avg | +56.1% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.4x Premium | +19% vs avg | -25.4% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.9x Fair | -2% vs avg | +12.2% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 38.5x Fair | +5% vs avg | -14.9% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 39.3x Fair | +7% vs avg | +28.1% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 39.0x Fair | +7% vs avg | +31.3% |
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 29.4x Undervalued | -20% vs avg | +21.9% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 27.7x Undervalued | -24% vs avg | +45.4% |
SHILPA MEDICARE LTD trades at a premium (53.1x vs peer avg 36.6x), implying higher growth or quality expectations from the Pharmaceuticals cohort. Peers include AKUMS DRUGS AND PHARMA L, BLUE JET HEALTHCARE LTD, GLENMARK PHARMACEUTICALS — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹166 CrDec 2025Latest net profit
₹25 CrDec 2025Latest EPS
₹0.84Dec 2025Net margin
10.5%Dec 2025Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Dec 2025
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 66.5 | 37.83 | 74.61 | 63.98 | 87.45 | 96.12 | 130 | 125 | 126 | 92.43 | 135 | 166 |
| Expenses | 80.27 | 68.4 | 67.32 | 67.28 | 80.5 | 72.77 | 86.82 | 103 | 91.39 | 75.44 | 95.79 | 135 |
| Operating Profit | -25.75 | -42.83 | -5.38 | -15.69 | -5.34 | 11.05 | 30.84 | 10.27 | 22.42 | 4.4 | 25.99 | 17.43 |
| OPM % | -38.72% | -113.22% | -7.21% | -24.52% | -6.11% | 11.5% | 23.78% | 8.19% | 17.77% | 4.76% | 19.26% | 10.52% |
| Other Income | 20.33 | 20.78 | 22.76 | 22.33 | 23.25 | 31.4 | 21.47 | 16.26 | 13.91 | 17.79 | 16.94 | 11.29 |
| Interest | 6.61 | 6.76 | 5.18 | 2.61 | 2.71 | 1.77 | 1.19 | 1.19 | 1.91 | 2.23 | 2.44 | 2.74 |
| Depreciation | 11.98 | 12.26 | 12.67 | 12.39 | 12.29 | 12.3 | 12.02 | 12.2 | 12.34 | 12.59 | 13.15 | 13.56 |
| Profit before tax | -12.03 | -28.81 | 12.2 | 4.03 | 15.2 | 40.68 | 51.12 | 25.34 | 34.42 | 19.96 | 40.49 | 25.98 |
| Tax % | -24.94% | -9.93% | 44.18% | 30.02% | 11.05% | 30.33% | 39.44% | 36.35% | -12.43% | 52.66% | 32.33% | 4.97% |
| Net Profit | -15.03 | -31.67 | 6.81 | 2.82 | 13.52 | 28.34 | 30.96 | 16.13 | 38.7 | 9.45 | 27.4 | 24.69 |
| EPS in Rs | -3.33 | -4.38 | 0.76 | 0.31 | 1.12 | 2.89 | 3.12 | 1.65 | -0.58 | 2.12 | 1.58 | 0.84 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.